Welcome to our dedicated page for Enochian Biosciences news (Ticker: ENOB), a resource for investors and traders seeking the latest updates and insights on Enochian Biosciences stock.
Enochian Biosciences, Inc. (ENOB) is a pioneering biopharmaceutical company headquartered in Los Angeles, California. Formerly known as Dandrit Biotech USA Inc., Enochian focuses on developing and commercializing groundbreaking therapies aimed at transforming immunotherapy treatments for HIV/AIDS and cancer.
The company's leading candidate, ENO-1001, is in the pre-Investigational New Drug (pre-IND) stage and has potential as a sterilizing cure for HIV/AIDS. In addition to ENO-1001, Enochian is working on ENO-2001, an HIV vaccine currently in the preclinical stage. The company is also focusing on innovative compounds such as ENO-4001 (a phase three asset), ENO-4002, ENO-5001, and ENO-3001 for the prevention of relapse in colon cancer patients.
Enochian Biosciences has recently faced a significant event where their Annual Meeting required adjournment due to the lack of a quorum. The meeting has been rescheduled to July 21, 2023, at 12:00 p.m. (Eastern Time). The company continues to solicit votes from its stockholders to meet the required quorum. Valid proxies and votes already submitted will still be effective unless revoked, and the company encourages all eligible stockholders to participate.
Enochian Biosciences operates with a clear focus on research and development, continually working on their clinical trials and product development activities. The company is actively engaged in securing regulatory approvals for its products and is strategically positioned for potential future growth. Investors are advised to stay updated with the company's latest developments and filings with the United States Securities and Exchange Commission (SEC).
For more information, stockholders and interested parties can access the company's proxy statement and annual reports, or attend the virtual Annual Meeting.
Enochian BioSciences (NASDAQ: ENOB) announced promising findings presented by Dr. Serhat Gumrukçu at the International Liver Conference, showing that a novel cellular therapy reduced Hepatitis B Virus (HBV) to undetectable levels by the 8th day without toxicities. The company holds an exclusive license for this technology, Hijack RNA, which also shows potential against influenza and coronaviruses, including COVID-19. These advancements could impact global health, particularly for the 350 million HBV patients worldwide.
Enochian BioSciences has acquired an exclusive license for a novel technology aimed at treating and preventing all variants of coronavirus, including COVID-19, and influenza. The company plans to submit a request for a Pre-Investigator New Drug meeting with the FDA shortly. This innovative technology employs nanoparticles to induce infected cells to self-destruct, potentially allowing a single inhalation to provide both treatment and long-term protection against infections. The technology targets a common region in SARS-CoV-2 variants, offering hope amid concerns over vaccine effectiveness.
Enochian BioSciences (NASDAQ: ENOB) is advancing a promising HIV treatment closer to FDA approval. The Seraph Research Institute (SRI), led by Dr. Serhat Gumrukcu, has secured a Pre-Investigational New Drug (Pre-IND) meeting with the FDA to discuss its immune-based cell therapy. Initial results from a patient's treatment indicate a sustained undetectable viral load, potentially allowing for a functional cure. This milestone may pave the way for alternative HIV treatments beyond daily antiviral medications.
Enochian BioSciences, Inc. has announced a definitive securities purchase agreement to issue 3,866,667 shares at $7.50 each, raising approximately $29 million before fees. The registered direct offering, expected to close around June 16, 2021, aims to fund working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent. This offering is being conducted under a shelf registration statement filed with the SEC. The company focuses on gene-modified therapies targeting infectious diseases and cancer.
Enochian BioSciences has announced that the FDA accepted its Pre-IND request for a potential functional cure for HIV. This follows the promising results from a 54-year-old patient who achieved viral control for 255 days using Natural Killer and Gamma Delta T-cells without antiviral drugs. The findings will be further evaluated in a larger population to explore treatment possibilities for those with suppressed HIV. Experts in the field express optimism about the potential to alleviate the burden of daily antiviral medications.
Enochian BioSciences announced promising preliminary data on a novel cell therapy for HIV, presented by Dr. Serhat Gumrukçu at the ASGCT Annual Meeting. A 54-year-old patient, after 35 years of HIV infection, showed significant declines in viral load post-treatment. The therapy, involving NK and gamma delta T-cells, resulted in undetectable HIV levels after 100 days and sustained this status for 255 days without antiviral medication. The company is pursuing FDA approval to expand testing, which may lead to a functional cure for HIV and address unmet medical needs in treatment options.
LOS ANGELES, May 12, 2021 /PRNewswire/ -- Enobia (NASDAQ: ENOB) unveiled promising results of a novel HIV cell therapy presented by Dr. Serhat Gumrukçu at the ASGCT meeting. A 54-year-old HIV patient showed a decline in viral load to below detectable levels (<20 copies/ml) after receiving immune-based cell therapy over 100 days. Dr. Phillip Musikanth discussed the innovative approach utilizing natural killer and gamma delta T-cells. This study marks a significant advancement in HIV treatment, with ongoing regulatory application for clinical trials.
Enochian BioSciences (NASDAQ: ENOB) announced promising preliminary data regarding a new cell therapy aimed at controlling HIV in humans. Presented by Dr. Serhat Gumrukçu at the ASGCT Annual Meeting, the therapy involved a single patient who had been HIV-positive since 1986. Following treatment with natural killer and gamma delta T-cells, the patient's HIV levels dropped below detectable limits for over 255 days, even without antiviral medication. This approach could lead to a functional cure for HIV, with Enochian pursuing further research through the FDA.
Enochian BioSciences (NASDAQ: ENOB) and Seraph Research Institute announced a significant clinical outcome: a 36-year-old patient with recurrent glioblastoma achieved complete remission for 15 months. This case highlights a rare response to this aggressive brain cancer, documented in the American Journal of Case Reports. The patient was treated with genetically modified immune cells loaded with a cytomegalovirus component often found in glioblastomas. Enochian is advancing this technology for potential applications in pancreatic cancer and other solid tumors.
Enochian BioSciences will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021. Executive Vice Chair Dr. Mark Dybul will discuss advancements in the company's HIV, Hepatitis B, and Oncology platforms. The presentation will be accessible on-demand starting at 7 am Eastern. On March 10, Dr. Dybul and CFO Luisa Puche will engage in live one-on-one meetings with registered investors. For more details, attendees can visit the conference website.
FAQ
What is the market cap of Enochian Biosciences (ENOB)?
What does Enochian Biosciences do?
Where is Enochian Biosciences headquartered?
What is ENO-1001?
What stage is ENO-2001 in?
What are some other compounds Enochian is working on?
When is the rescheduled Annual Meeting?
How can stockholders vote for the proposals?
Who is helping Enochian with the voting process?
Where can I find the proxy statement and annual reports?
How can I attend the virtual Annual Meeting?
